Venture Capital: Biopharma Startup Mironid Extends Series A Round, Cumulatively Raising £35M

September 13, 2023 | News, Venture Capital

Mironid is developing small molecule therapeutics for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), a life-threatening hereditary kidney disease.

Mironid, a biopharmaceutical company headquartered in Glasgow, Scotland, is making significant strides in the development of innovative treatments for Autosomal Dominant Polycystic Kidney Disease (ADPKD), a life-threatening hereditary kidney condition. On September 13, 2023, the company announced an extension of its Series A financing round, securing an impressive total of £35 million in funding to date. This achievement is a testament to Mironid’s promising drug development strategy.

The funding round received a substantial boost from Roche Venture Fund, a new investor joining existing major backers like Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, the University of Strathclyde, Scottish Enterprise, and the European Investment Fund. This collaboration underscores the industry’s recognition of Mironid’s potential to make a meaningful impact in the treatment of ADPKD.

ADPKD is a prevalent rare disease, affecting over 12 million individuals globally, with a significant portion facing kidney failure by the age of 60. Mironid’s pioneering LoAc® small molecules target cyclic AMP (cAMP), a key cellular signal implicated in all stages of ADPKD. Extensive research has shown promising results, including a reduction in cyst number and kidney volume, suggesting potential clinical benefits for all ADPKD patients.

Additionally, this drug class offers the prospect of an improved side-effect profile, addressing a key concern in current therapies.

With this latest funding, Mironid is poised to advance its lead discovery program and expand its patent portfolio. The company’s dedication to combating ADPKD and improving patients’ lives is underscored by its impressive financial backing and the potential of its groundbreaking small molecule therapeutics.

Related Story: Genesis Therapeutics Closes $200M Round To Expand AI-Powered Drug Discovery

Image by Colin Behrens from Pixabay

Free Industry News

Subscribe to our free newsletter for updates and news about alternatives investments.

  • This field is for validation purposes and should be left unchanged.


Latest Alternative Investment News
Artificial Intelligence: AMD Takes On Rivals In The AI Chip Sweepstakes
December 7, 2023     Artificial Intelligence, News

Chipmaker AMD (NASDAQ: AMD) has unveiled a range of innovative AI solutions spanning from data centers to personal computers. The AMD Instinct MI300 Series features data center AI accelerators, while…
Digital Assets: Robinhood Debuts Crypto Trading On Its App In The EU
December 7, 2023     Digital Assets, FinTech, News

Robinhood (NASDAQ: HOOD) has launched its Crypto app in the European Union (EU), allowing eligible customers to engage in crypto trading with the added incentive of earning Bitcoin rewards. Customers…
FinTech: Samsung Electronics Ties With Mastercard’s Wallet Express
December 7, 2023     FinTech, News

Samsung Electronics (KRX: 005930) and Mastercard (NYSE: MA) have partnered to launch the Wallet Express program, offering banks and card issuers a cost-effective way to expand digital wallet offerings. Through…
Venture Capital: Revaia, Europe’s Biggest Female-Led VC Firm, Racks Up $160M For Second Fund
December 7, 2023     ESG and Sustainability, News, Venture Capital

Revaia, Europe’s largest female-founded venture capital firm, has successfully raised €150 million ($160 million) for its second fund, Revaia Growth II. The funding was secured from sovereign wealth funds, family…